Comparison of the efficacy and safety Lispro 50 and Lispro 25 after 16 weeks in Chinese patients with type 2 diabetes who received basal insulin therapy with substandard blood glucose

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036872

Enrollment

Unknown

Registered

2020-08-25

Start date

2020-08-28

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Group 1:Lispro 50

Group 2:Lispro25

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Chinese patients with type 2 diabetes aged 18 to 75 years; 2. At the time of screening, basal insulin treatment >=6 months (subject to medical history). According to the patient's condition, researchers communicated with the patient and decided that premixed insulin treatment was needed; 3. In the last 4 weeks, the tested value of HbA1c 7.5% to 11%; 4. Stable administration of metformin at the maximum tolerated dose; 5. BMI 18.5 - 35.0 kg/m2.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes; 2. Severe hypoglycemia in patients with T2DM; 3. Malignant tumor, acute infection; 4. drug allergy; 5. Being pregnant, breastfeeding or planning to become pregnant during the study period.

Design outcomes

Primary

Measure	Time frame
HBAIC;	—

Secondary

Measure	Time frame
FBS;PBG;	—

Countries

China

Contacts

Public ContactLi Yan

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

liyan19642012@sina.com+86 18620414146

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026